Clinical Trial

Generated on 25 Apr 2025 from the

Title	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Protocole ID	CA052-002
ClinicalTrials.gov ID	NCT04895709
Cancer Type(s)	Tumeurs solides
Phase	Phase I-II
Stage	Maladie avancée ou métastatique
Study Type	Clinique
Drug	BMS-986340 en monothérapie ou en association avec le nivolumab
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
City	
Principal Investigator	
Coordinator	
Status	Actif en recrutement
Eligibility Criteria	• Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy • Eastern Cooperative Oncology Group Performance Status of 0 or 1 • Radiographically documented progressive disease on or after the most recent therapy • Received standard-of-care therapies, including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated • Parts 1A, 1B, and 2A: Advanced or metastatic non-small cell lung cancer, squamous cell carcinoma of head and neck, microsatellite stable colorectal cancer, gastric/ gastroesophageal junction adenocarcinoma, or cervical cancer, and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant
Exclusion Criteria	• Women who are pregnant or breastfeeding • Primary central nervous system (CNS) malignancy • Untreated CNS metastases • Leptomeningeal metastases • Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment • Active, known, or suspected autoimmune disease • Condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment • Prior organ or tissue allograft • Uncontrolled or significant cardiovascular disease • Major surgery within 4 weeks of study drug administration • History of or with active interstitial lung disease or pulmonary fibrosis Other protocol-defined inclusion/exclusion criteria apply